SCHEMBL11957888

SCHEMBL11957888

COc1cc(N=O)cc(OC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.58
▸ CYP1A1 P04798 2/20 0.44
▸ CYP1B1 Q16678 2/20 0.44
▸ KMT2A Q03164 3/20 0.41
▸ POLB P06746 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ PTGS2 P35354 1/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2E1 P05181 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C8 P10632 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2A6 P11509 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP4B1 P13584 1/20 0.39
▸ CYP2B6 P20813 1/20 0.39
▸ CYP3A5 P20815 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6030837 0.84 ALDH1A1 (0.40) ALDH1A1CYP1A1CYP1B1KMT2ANPC1
SCHEMBL20925070 0.84 ALDH1A1 (0.40) ALDH1A1MAPTSMN1; SMN2HTT
SCHEMBL14088888 0.84 ALDH1A1 (0.40) ALDH1A1KMT2AMAPTCYP1A2CYP3A4
SCHEMBL13073022 0.80 GRIN2D (0.40) ALDH1A1PTGS2
SCHEMBL10054152 0.78 PARP1 (0.51) KMT2APOLBNPC1MAPTRAB9A
SCHEMBL13690326 0.78 MEN1 (0.47) KMT2ANPC1MAPTRAB9ASMN1; SMN2
SCHEMBL3188871 0.78 ALDH1A1 (0.65) ALDH1A1CYP1A1CYP1B1KMT2APTGS2
SCHEMBL18433896 0.77 NOS3 (0.37) ALDH1A1KMT2APOLBCYP1A2CYP2E1
SCHEMBL5534468 0.77 HTR3E (0.58) ALDH1A1KMT2APOLBNPC1MAPT
1,3,5-Trimethoxybenzene SCHEMBL28493 0.76 ALDH1A1 (1.00) ALDH1A1CYP1A1CYP1B1PTGS2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236805-B2 Substituted piperazines as CB1 antagonists INTERVET INC. (US) 2012-08-07 — — US disclosed
US-7700597-B2 Substituted piperazines as CB1 antagonists SCHERING CORPORATION (US) 2010-04-20 — — US disclosed
US-7700597-B2 Substituted piperazines as CB1 antagonists SCHERING CORPORATION (US) 2010-04-20 — — US disclosed
US-20100029607-A1 Substituted Piperazines as CB1 Antagonists SCHERING CORPORATION 2010-02-04 — — US disclosed
US-20080076924-A1 Piperazines as P2X7 antagonists ABBOTT LABORATORIES 2008-03-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029607-A1 Substituted Piperazines as CB1 Antagonists CNR1, CNR2, GPR119 ALDH1A1 1520/4885CYP1A1 293/4885CYP1B1 507/4885
US-20080076924-A1 Piperazines as P2X7 antagonists P2RX7, P2RX1, P2RX2 ALDH1A1 852/4885CYP1A1 299/4885CYP1B1 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback